Trivalent anti-TRAIL-R1 nano-agonist molecule1

Drug Profile

Trivalent anti-TRAIL-R1 nano-agonist molecule1

Alternative Names: TTR nano-agonist molecule1; TTR1 agonist; TTR1 nano-agonist

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teikyo University
  • Developer SymBio Pharmaceuticals; Teikyo University
  • Class Antibodies
  • Mechanism of Action TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Feb 2017 Discontinued - Preclinical for Cancer in Japan (Parenteral)
  • 08 Feb 2016 SymBio Pharmaceuticals and Teikyo enter into a Joint Research and Development Agreement for development of TTR1 nanon-agonist molecule1
  • 08 Feb 2016 Preclinical trials in Cancer in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top